Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Post-allograft pomalidomide and reversible hepatotoxicity

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Kida A, McDonald GB . Gastrointestinal, hepatobiliary, pancreatic, and iron-related diseases in long-term survivors of allogeneic hematopoietic cell transplantation. Semin Hematol 2012; 49: 43–58.

    Article  Google Scholar 

  2. Nojkov B, Signori C, Konda A, Fontana RJ . Lenalidomide-associated hepatotoxicity – a case report and literature review. Anticancer Res 2012; 32: 4117–4120.

    PubMed  Google Scholar 

  3. Zanella M-C, Rubbia-Brandt L, Giostra E, Chalandon Y, Hadengue A, Spahr L . A case of drug-induced hepatitis due to lenalidomide. Case Rep Gastroenterol 2011; 5: 217–222.

    Article  Google Scholar 

  4. Hussain S . Lenalidomide-induced severe hepatotoxicity. Blood 2007; 110: 3814.

    Article  CAS  Google Scholar 

  5. Vilas-Boas F, Gonclaves R, Sobrinho SM, Lopes J, Macedo G . Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature. Gastroenterol Hepatol 2012; 35: 560–566.

    Article  Google Scholar 

  6. Shpall EJ . Lenalidomide-induced graft-vs-leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk 2014; 14: e105–e109.

    Article  Google Scholar 

  7. Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 2011; 118: 2413–2419.

    Article  CAS  Google Scholar 

  8. Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y et al. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I/II dose-finding study. Exp Hematol 2013; 41: 134–142.

    Article  CAS  Google Scholar 

  9. Coman T, Bachy E, Michallet M, Socié G, Uzunov M, Bourhis JH et al. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. Haematologica 2013; 98: 776–783.

    Article  CAS  Google Scholar 

  10. Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J 2013; 3: e143.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J M Pauff.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pauff, J., Gonzalez, R., Sajnani, K. et al. Post-allograft pomalidomide and reversible hepatotoxicity. Bone Marrow Transplant 49, 1341–1342 (2014). https://doi.org/10.1038/bmt.2014.128

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.128

This article is cited by

Search

Quick links